Why Alnylam Pharmaceuticals Rose 12.7% in November

In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13% in November according to data from S&P Global Market Intelligence.

Here's a review of the key announcements made during the month:

Given the news, it isn't hard to figure out why investors had yet another profitable month.

Source: Fool.com